Endo International PLC ENDP shares are trading lower by 34.65% at $1.32 after the company reported first-quarter earnings results and issued second-quarter guidance.
Endo International reported quarterly earnings of 66 cents per share which beat the analyst consensus estimate of 44 cents. The company also reported quarterly sales of $652.26 million which beat the analyst consensus estimate of $633.41 million by 3%.
Endo International sees second-quarter sales as low as $500 million or as high as $525 million and adjusted EBITDA as low as $110 million or as high as $125 million. Endo International also sees adjusted EPS in the range of a loss of 15 to 17 cents per share.
See Also: Why DoorDash Shares Are Rising Today
Endo International is a specialty pharmaceutical company with presence in pain management, urology, orthopedics, endocrinology and bariatrics.
According to data from Benzinga Pro, Endo International has a 52-week high of $7.07 and a 52-week low of $1.28.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
